Humoral- and T-Cell–Specific Immune Responses to SARS-CoV-2 mRNA Vaccination in Patients With MS Using Different Disease-Modifying Therapies

Disease modifying therapies and Covid‐19 severity in Multiple Sclerosis

(2021) Maria Pia Sormani et al.   ANNALS OF NEUROLOGY

Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection

(2021) Jennifer M. Dan et al.   SCIENCE

Diagnosis and Treatment of Multiple Sclerosis

(2021) Marisa P. McGinley et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Baricitinib Therapy in Covid-19 Pneumonia — An Unmet Need Fulfilled

(2021) Delia Goletti et al.   NEW ENGLAND JOURNAL OF MEDICINE

Spike is the most recognized antigen in the whole-blood platform in both acute and convalescent COVID-19 patients

(2021) Alessandra Aiello et al.   INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES

Prolonged and severe SARS-CoV-2 infection in patients under B-cell-depleting drug successfully treated: a tailored approach

(2021) Alessandra D’Abramo et al.   INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES

Disease-modifying therapies and SARS-CoV-2 vaccination in multiple sclerosis: an expert consensus

(2021) Diego Centonze et al.   JOURNAL OF NEUROLOGY

SARS-CoV-2 Serum Neutralization Assay: A Traditional Tool for a Brand-New Virus

(2021) Giulia Matusali et al.   Viruses-Basel

Interim Estimates of Vaccine Effectiveness of BNT162b2 and mRNA-1273 COVID-19 Vaccines in Preventing SARS-CoV-2 Infection Among Health Care Personnel, First Responders, and Other Essential and Frontline Workers — Eight U.S. Locations, December 2020–March 2021

(2021) Mark G. Thompson et al.   MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT

Preliminary evidence of blunted humoral response to SARS-CoV-2 mRNA vaccine in multiple sclerosis patients treated with ocrelizumab

(2021) Antonio Gallo et al.   NEUROLOGICAL SCIENCES

Impact of disease-modifying treatments on humoral response after COVID-19 vaccination: A mirror of the response after SARS-CoV-2 infection

(2021) K. Bigaut et al.   REVUE NEUROLOGIQUE

Anti-CD20 antibody therapy and risk of infection in patients with demyelinating diseases

(2021) N.R. Oksbjerg et al.   Multiple Sclerosis and Related Disorders

ImmunosuppressiveTherapies Differently Modulate Humoral- and T-Cell-Specific Responses to COVID-19 mRNA Vaccine in Rheumatoid Arthritis Patients

(2021) Andrea Picchianti-Diamanti et al.   Frontiers in Immunology

Impact of Prior Influenza and Pneumoccocal Vaccines on Humoral and Cellular Response to SARS-CoV-2 BNT162b2 Vaccination

(2021) Vincenzo Puro et al.   Vaccines

Coordinate Induction of Humoral and Spike Specific T-Cell Response in a Cohort of Italian Health Care Workers Receiving BNT162b2 mRNA Vaccine

(2021) Chiara Agrati et al.   Microorganisms

SARS-CoV-2-reactive T cells in healthy donors and patients with COVID-19

(2020) Julian Braun et al.   NATURE

Effect of ocrelizumab on vaccine responses in patients with multiple sclerosis: The VELOCE study

(2020) Amit Bar-Or et al.   NEUROLOGY

Antigen-Specific Adaptive Immunity to SARS-CoV-2 in Acute COVID-19 and Associations with Age and Disease Severity

(2020) Carolyn Rydyznski Moderbacher et al.   CELL

Interferon-gamma release assay for accurate detection of SARS-CoV-2 T cell response

(2020) Kanagavel Murugesan et al.   CLINICAL INFECTIOUS DISEASES

A whole blood test to measure SARS-CoV-2 specific response in COVID-19 patients

(2020) Linda Petrone et al.   CLINICAL MICROBIOLOGY AND INFECTION

Immune Therapy, or Antiviral Therapy, or Both for COVID-19: A Systematic Review

(2020) Fabrizio Cantini et al.   DRUGS

Trends and characteristics of infection-related hospital admissions in multiple sclerosis patients in Southwest Finland in 2009–2018

(2020) Anna-Leena Pirttisalo et al.   Multiple Sclerosis and Related Disorders

Mild clinical manifestations of SARS-CoV-2 related pneumonia in two patients with multiple sclerosis under treatment with ocrelizumab

(2020) Marco Iannetta et al.   Multiple Sclerosis and Related Disorders

Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine

(2020) Lindsey R. Baden et al.   NEW ENGLAND JOURNAL OF MEDICINE

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

(2020) Fernando P. Polack et al.   NEW ENGLAND JOURNAL OF MEDICINE

Effect of cladribine tablets on lymphocyte reduction and repopulation dynamics in patients with relapsing multiple sclerosis

(2019) Giancarlo Comi et al.   Multiple Sclerosis and Related Disorders

Infection Risks Among Patients With Multiple Sclerosis Treated With Fingolimod, Natalizumab, Rituximab, and Injectable Therapies

(2019) Gustavo Luna et al.   JAMA Neurology

Antibody response to seasonal influenza vaccination in patients with multiple sclerosis receiving immunomodulatory therapy

(2018) H. K. Olberg et al.   EUROPEAN JOURNAL OF NEUROLOGY

Cladribine treatment of multiple sclerosis is associated with depletion of memory B cells

(2018) Bryan Ceronie et al.   JOURNAL OF NEUROLOGY

Cladribine: mechanisms and mysteries in multiple sclerosis

(2018) Benjamin Meir Jacobs et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria

(2018) Alan J Thompson et al.   LANCET NEUROLOGY

Update on tuberculosis biomarkers: From correlates of risk, to correlates of active disease and of cure from disease

(2018) Delia Goletti et al.   RESPIROLOGY

Disease-modifying therapies and infectious risks in multiple sclerosis

(2016) Alexander Winkelmann et al.   Nature Reviews Neurology

Randomized trial of vaccination in fingolimod-treated patients with multiple sclerosis

(2015) L. Kappos et al.   NEUROLOGY

How many events is enough? Are you positive?

(2008) Mario Roederer   CYTOMETRY PART A